FUJIFILM
146 articles about FUJIFILM
-
Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks
5/21/2020
Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, announced that Health Canada provided regulatory clearance for Appili’s Phase 2 study evaluating FUJIFILM Toyama Chemical’s favipiravir as a preventative measure against COVID-19 outbreaks.
-
Fujifilm Announces Appointment Of FUJIFILM Sonosite's Rich Fabian To Board Of AdvaMed
5/20/2020
Fabian, President and COO of FUJIFILM Sonosite, Inc., applauds AdvaMed for its leadership in times of health crisis
-
Appili Therapeutics Submits CTA with Health Canada to Sponsor Prophylactic Phase 2 Clinical Trial Evaluating FUJIFILM Toyama Chemical’s Favipiravir as a Preventative Measure Against COVID-19 in Canadian Long-Term Care Facilities
5/11/2020
First clinical program in the world designed to assess the use of favipiravir for COVID-19 as prophylaxis for outbreak control; antiviral drug has shown early efficacy against COVID-19
-
CMIC Group Supports Clinical Trials and Manufacturing of Influenza Antiviral Drug “Avigan® Tablet” and Contributes to Accelerating Provision for COVID-19 Patients
4/23/2020
CMIC HOLDINGS Co., Ltd. announced that CMIC is providing monitoring services as a CRO for “Avigan® Tablet”, a product that FUJIFILM Toyama Chemical Co., Ltd. gained approval in Japan for manufacture and sale as an influenza antiviral drug, phase III clinical trial in Japan and will support for manufacturing the product as a CDMO..
-
Fujifilm accelerates production of its influenza antiviral drug "Avigan® Tablet" for COVID-19
4/15/2020
FUJIFILM Corporation has announced that it has expanded its manufacturing capacity at FUJIFILM Toyama Chemical Co., Ltd. to significantly increase production of its influenza antiviral drug "Avigan® Tablet" for treating patients with COVID-19..
-
BioSpace Movers & Shakers, March 20
3/20/2020
Companies strengthen their leadership teams and board with this week's Movers & Shakers. -
FujiFilm itself has not commented on the reports from China, The Guardian noted.
-
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
-
SMART Medical Systems Launches its G-EYE® 760R Colonoscope in the European Endoscopy Market Through FUJIFILM Europe, Under Strategic Distribution Partnership With FUJIFILM, to Provide Synergetic Colonoscopy Solution in Fight Against Colon Cancer
2/6/2020
SMART's G-EYE® 760R colonoscope, incorporating its G-EYE® Balloon Technology designed to increase the detection of cancerous polyps in colonoscopy, will become available by FUJIFILM Europe with its state-of-the-art ELUXEO system, as part of the newly formed strategic distribution partnership with FUJIFILM Corporation.
-
FUJIFILM Corporation Announces Plans For Operating Room And Interventional Systems Integration Business
1/21/2020
Industry leader to present the market with a one-stop, single-vendor solution for medical image capture, management, storage, and image enablement
-
FUJIFILM Corporation will invest 13 billion yen (about $120 million) to expand the company’s gene therapy business and establish a new Gene Therapy Innovation Center adjacent to its current facility in College Station, Texas and add about 100 jobs.
-
Fujifilm announces expansion of its biopharmaceutical contract development and manufacturing business capital investment totaling approximately 13 billion yen committed to expand gene therapy capabilities
11/14/2019
Establishing a New Gene Therapy Drug Process Development Building and Expanding Product Facilities in Texas, USA
-
FUJIFILM SonoSite Exhibits Portfolio Of Point-Of-Care Ultrasound Solutions At ASA 2019
10/17/2019
Company demonstrates suite of imaging and educational solutions to more than 14,000 anesthesia professionals
-
FUJIFILM SonoSite, Inc. Signs Agreement With Intelligent Ultrasound Group plc To Develop Clinician Training
10/17/2019
The agreement includes Intelligent Ultrasound Group's BodyWorks Eve POCUS training solution and the HeartWorks transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) simulator training platforms that can be used to accelerate training for all Fujifilm SonoSite's POCUS systems.
-
Fujifilm Showcases Complete Suite Of Solutions At CHEST 2019
10/17/2019
Industry leader presents two new pulmonary imaging devices
-
Fujifilm Completes Acquisition of Biogen’s Manufacturing Site in Denmark-August 1, 2019
8/1/2019
FUJIFILM Corporation announced that it has completed the acquisition of Biogen Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark from Biogen.
-
Fujifilm Completes Acquisition of Biogen's Manufacturing Site in Denmark
8/1/2019
FUJIFILM Corporation ("Fujifilm") today announced that it has completed the acquisition of Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark ("Hillerød Manufacturing") from Biogen.
-
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
-
Fujifilm Now An OpenMarkets Active Supplier For Entire Portfolio Of Minimally Invasive Surgical Technologies
7/1/2019
FUJIFILM New Development, U.S.A., Inc., an innovative provider of minimally invasive surgical solutions, is now an active supplier with OpenMarkets, a software-driven marketplace for healthcare equipment connecting healthcare professionals with healthcare solutions suppliers.
-
FUJIFILM Corporation Announces the Introduction of a Novel, Fully Integrated Continuous Production System for the Manufacture of Biopharmaceuticals
6/5/2019
FUJIFILM Corporation, announced an initial $10M USD investment to establish a full scale, fully integrated continuous processing facility for non-GMP manufacture of biopharmaceuticals at its FUJIFILM Diosynth Biotechnologies, Billingham, UK location.